The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling, Marc J. Van De Vijver, Emiel J.Th Rutgers, Marie Jeanne T.F.D. Vrancken Peeters, Harm Van Tinteren, Laura J. Van'T Veer, Sjoerd Rodenhuis

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

209 Citaten (Scopus)

Samenvatting

The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

Originele taal-2Engels
Pagina's (van-tot)551-558
Aantal pagina's8
TijdschriftBreast Cancer Research and Treatment
Volume119
Nummer van het tijdschrift3
DOI's
StatusGepubliceerd - feb. 2010
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer'. Samen vormen ze een unieke vingerafdruk.

Citeer dit